AUSTIN, Texas, June 26, 2012 /PRNewswire/ -- Prodigy Health Supplier entered a Joint Venture with Stason Pharmaceuticals to bring a diverse line of quality generic pharmaceuticals to the U.S. market. This relationship represents a combined commitment to providing the highest quality generic drugs with a consistent supply and a competitive price.
The partnership supports robust research and development with 30 PhDs on staff and over 120 people in that department. Core generic therapeutic categories include oncology, central nervous system (CNS), cardiovascular and dermatologic indications. Delivery mechanisms for the drugs include capsules and oral solids as well as new delivery mechanisms.
Bryan Sanders, president of Prodigy Health Supplier, states, "Quality manufacturing in Stason will provide excellent long term value to our business as well as the generic pharmaceutical market. Three of our current registrations are found on the national FDA shortage list and we are dedicated to bringing these products to market as soon as possible to help alleviate this strain. There are 7 drugs in our present pipeline that will be released over the next two years and we are evaluating additional items on the shortage list for potential registration and production."
Prodigy Health Supplier Corporation (PHS), a privately held company, was established in 2001 and is based in Austin, Texas. Since inception PHS has been a consistent and dependable supplier in the bio-pharmaceutical industry and has grown into one of the leading suppliers of plasma derivatives and injectables in the United States. PHS launched their generics division in 2010 and partners with proven manufacturers to provide a strong portfolio of generic drugs to the U.S. market. More information about PHS can be found at www.phscorporation.com.
Stason Pharmaceuticals, Inc., established in 1994 and based in Irvine, CA is a privately-held, global pharmaceutical company involved in drug development, manufacturing, importation/exportation, licensing and marketing of both generic and branded products. The company's primary area of development is in the area of oncology, and supportive products for the treatment of side effects related to cancer therapy. Additional therapeutic areas include cardiovascular, central nervous system, autoimmune and endocrine disorders. Additional information about Stason can be found at www.stasonpharma.com.
SOURCE Prodigy Health Supplier Corporation
